2019/08/14 by Robert H. Vonderheide · 558 citations
Immunology and Microbiology · Medicine · #Agonist #Antibody #Cancer #Cancer Immunotherapy and Biomarkers #Immunology #Immunotherapy #Immunotherapy and Immune Responses #Internal medicine #Medicine #Monoclonal and Polyclonal Antibodies Research #Receptor
paper · doi:10.1146/annurev-med-062518-045435
published in Annual Review of Medicine 71(1), 47-58 (Annual Reviews)
openalex publication_date 2019/08/14 · openalex created_date 2025/10/10 · openalex updated_date 2026/08/06
CD40 is a cell-surface member of the TNF (tumor necrosis factor) receptor superfamily. Upon activation, CD40 can license dendritic cells to promote antitumor T cell activation and re-educate macrophages to destroy tumor stroma. Numerous agonist CD40 antibodies of varying formulations have been evaluated in the clinic and found to be tolerable and feasible. Administration is associated with mild to moderate (but transient) cytokine release syndrome, readily managed in the outpatient setting. Antitumor activity with or without anti-CTLA4 monoclonal antibody (mAb) therapy has been observed in patients with melanoma, and major tumor regressions have been observed in patients with pancreatic cancer, mesothelioma, and other tumors in combination with chemotherapy. In a recent study of chemotherapy plus CD40 mAb, with or without PD-1 mAb, the objective response rate in patients with untreated, metastatic pancreatic cancer was >50%. Mechanistically, the combination of chemotherapy followed by CD40 mAb functions as an in situ vaccine; in addition, destruction of stroma by CD40-activated macrophages may enhance chemotherapy delivery. Evidence to date suggests that CD40 activation is a critical and nonredundant mechanism to convert so-called cold tumors to hot ones (with prominent tumor infiltration of T cells), sensitizing them to checkpoint inhibition.